BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35105934)

  • 1. Analysis of the effect of NEKs on the prognosis of patients with non-small-cell lung carcinoma based on bioinformatics.
    Yang M; Guo Y; Guo X; Mao Y; Zhu S; Wang N; Lu D
    Sci Rep; 2022 Feb; 12(1):1705. PubMed ID: 35105934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.
    Chen C; Peng S; Li P; Ma L; Gan X
    Mol Cell Biochem; 2020 Dec; 475(1-2):15-25. PubMed ID: 32761510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis.
    Gong K; Zhou H; Liu H; Xie T; Luo Y; Guo H; Chen J; Tan Z; Yang Y; Xie L
    Technol Cancer Res Treat; 2021; 20():15330338211060202. PubMed ID: 34825846
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
    Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
    Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of TIMELESS and RORA as key clock molecules of non-small cell lung cancer and the comprehensive analysis.
    Xian H; Li Y; Zou B; Chen Y; Yin H; Li X; Pan Y
    BMC Cancer; 2022 Jan; 22(1):107. PubMed ID: 35078435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
    Zeng Y; Li N; Liu W; Zeng M; Cheng J; Huang J
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2447-2460. PubMed ID: 32627077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
    Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
    Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct expression and prognostic value of members of SMAD family in non-small cell lung cancer.
    Zeng Z; Yang Y; Qing C; Hu Z; Huang Y; Zhou C; Li D; Jiang Y
    Medicine (Baltimore); 2020 Mar; 99(10):e19451. PubMed ID: 32150102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative Analysis of the Expression Levels and Prognostic Values for NEK Family Members in Breast Cancer.
    Gao WL; Niu L; Chen WL; Zhang YQ; Huang WH
    Front Genet; 2022; 13():798170. PubMed ID: 35368696
    [No Abstract]   [Full Text] [Related]  

  • 12. Elevated integrin α6β4 expression is associated with venous invasion and decreased overall survival in non-small cell lung cancer.
    Stewart RL; West D; Wang C; Weiss HL; Gal T; Durbin EB; O'Connor W; Chen M; O'Connor KL
    Hum Pathol; 2016 Aug; 54():174-83. PubMed ID: 27107458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
    Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.
    Nagy Á; Pongor LS; Szabó A; Santarpia M; Győrffy B
    Int J Cancer; 2017 Feb; 140(4):930-937. PubMed ID: 27859136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.
    You Q; Guo H; Xu D
    Drug Des Devel Ther; 2015; 9():5087-97. PubMed ID: 26366059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis.
    Zhong X; Guan X; Dong Q; Yang S; Liu W; Zhang L
    Tumour Biol; 2014 Jul; 35(7):7155-62. PubMed ID: 24763826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of NEK2 is correlated with poor prognosis in human clear cell renal cell carcinoma.
    Wang C; Huang Y; Ma X; Wang B; Zhang X
    Int J Immunopathol Pharmacol; 2021; 35():20587384211065893. PubMed ID: 34910592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value and therapeutic potential of NEK family in stomach adenocarcinoma.
    Zhou X; Nie H; Wang C; Yu X; Yang X; He X; Ou C
    J Cancer; 2024; 15(10):3154-3172. PubMed ID: 38706902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced expression of circular RNA hsa_circ_000984 promotes cells proliferation and metastasis in non-small cell lung cancer by modulating Wnt/β-catenin pathway.
    Li XY; Liu YR; Zhou JH; Li W; Guo HH; Ma HP
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3366-3374. PubMed ID: 31081091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of high expression levels of STK39 in the growth, migration and invasion of non-small cell type lung cancer cells.
    Li Z; Zhu W; Xiong L; Yu X; Chen X; Lin Q
    Oncotarget; 2016 Sep; 7(38):61366-61377. PubMed ID: 27542260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.